Clinical heterogeneity and treatment response in inclusion body myositis

Inclusion body myositis has been described as an inflammatory myopathy with distinctive clinical and pathologic features that is refractory to treatment. Ten cases of inclusion body myositis, as defined by histopathologic findings, were reviewed to determine whether the clinical characteristics are...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis and rheumatism 1989-06, Vol.32 (6), p.734-740
Main Authors: Cohen, Miriam Richter, Sulaiman, A. R., Garancis, John C., Wortmann, Robert L.
Format: Article
Language:English
Subjects:
Adult
Aged
Azathioprine - therapeutic use
Biological and medical sciences
Female
Humans
Inclusion Bodies - pathology
Inclusion Bodies - ultrastructure
Male
Medical sciences
Microscopy, Electron
Middle Aged
Myositis - drug therapy
Myositis - pathology
Neurology
Prednisone - therapeutic use
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inclusion body myositis has been described as an inflammatory myopathy with distinctive clinical and pathologic features that is refractory to treatment. Ten cases of inclusion body myositis, as defined by histopathologic findings, were reviewed to determine whether the clinical characteristics are different in patients whose disease has been defined by light and electron microscopic studies compared with those whose disease has been defined by light microscopic studies alone. The clinical characteristics of both groups of patients were similar, and 2 patients have had excellent responses to treatment. Although inclusion body myositis represents a histologic subset of polymyositis, from a clinical perspective, it must be considered a nonspecific designation. Despite a generally poor prognosis, therapeutic intervention is still warranted.
ISSN:0004-3591
1529-0131
DOI:10.1002/anr.1780320611